Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NKR-2 in colorectal cancer liver metastases
NCT03370198Phase 1Terminated
- Sponsor
- Celyad Oncology
- Start
- Oct 2017
- Primary completion
- Jan 2018
- Modality
- CAR-T Cells
- Countries
- 1
01
Overview
Phase 1, open-label trial of CAR-NKG2D in colorectal cancer (CRC) (3 arms), sponsored by Celyad Oncology. Primary endpoint: Dose-Limiting Toxicities at Day 43. Started Oct 2017; status: terminated.
02
Drugs
CAR-NKG2D
03
Conditions
colorectal cancer (CRC)
Beyond the preview
Go deeper on NCT03370198.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03370198.